New DrugDev Webinar Demystifies Common Myths of Electronic Informed Patient Consent Including Regulatory Challenges, Site Adoption Rates, Timelines and Cost
New DrugDev Webinar Demystifies Common Myths of Electronic Informed Patient Consent Including Regulatory Challenges, Site Adoption Rates, Timelines and Cost
Electronic patient consent visionary Eric Delente, DrugDev President of Patient Consent, to discuss the current state of technology and answer live questions from attendees
Philadelphia PA and London UK – Despite its rapid growth in global clinical studies, common misconceptions regarding electronic informed patient consent have potentially slowed adoption and delayed the ability for sponsors, CROs, sites, and most importantly patients to realize the proven benefits of this innovative and valuable mobile technology.
To learn the truth about patient consent, join a fact-packed webinar that will provide real-world information, results and insights on the practical benefits of implementation from the industry’s foremost visionary eConsent technologist, DrugDev President of Patient Consent, Eric Delente. Agenda topics include:
- Evidence-based results of increased patient comprehension, satisfaction, and retention vs. paper consent methods
- Global regulations and their potential impact on eConsent and eSignature
- The truth behind site adoption and best practices to get them excited
- Realistic total cost of ownership and implementation timelines as observed from over 100 eConsent clinical trials implemented by DrugDev
Webinar: Everything You’ve Heard about Electronic Patient Consent is (Probably) Wrong
Date: January 23, 2018
Time: 10-10:30am and 2-2:30pm EST (two live sessions offered)
Presenter: Eric Delente, DrugDev President, Patient Consent
“One of the biggest problems our industry faces is ensuring patients develop trust and feel satisfied with their clinical trial experience,” said Delente. “Research studies consistently show that not properly understanding consent documents leads to incorrect expectations that have a profound negative impact on patient satisfaction and ultimately retention rates. Electronic informed consent has been proven to solve these challenges, yet some study teams have been hesitant to adopt the technology due to understandable but inaccurate assumptions and myths. In this webinar, I will present common misconceptions and present facts and strategies based on real experience with top-10 pharmaceutical companies so attendees can get the facts and make up their own minds whether eConsent is right for them, for their sites, and most importantly for their patients worldwide.”
Delente has worked in the academic, medical and scientific communities for over 20 years, designing and developing award-winning educational portals and tools for healthcare and science. Delente co-founded SecureConsent, which DrugDev acquired in 2016 to integrate its groundbreaking mobile eConsent technology into the DrugDev Spark™ clinical operations suite. Eric is a member of the 2017 PharmaVOICE 100 most influential and inspiring people in the life sciences industries. Click here to read his recent thought-provoking article in Clinical Informatics News.
About DrugDev
DrugDev, an IQVIA company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.